Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Intravenous Imatinib Mesylate (Impentri®) in Subjects With Acute Respiratory Distress Syndrome Induced by COVID-19

NCT04794088 is registered in ClinicalTrials.gov with Dr. Jurjan Aman as lead sponsor.

NCT NCT04794088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04794088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of Intravenous Imatinib Mesylate (Impentri®) in Subjects With Acute Respiratory Distress Syndrome Induced by COVID-19
Lead sponsor
Dr. Jurjan Aman
Phase
Phase 2
Overall status
Terminated
Start date
March 14, 2021
Completion date
April 7, 2022
Enrollment
67 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute respiratory distress syndrome, ards, covid19, endothelial dysfunction, pulmonary edema